Radiopharmaceutical Theranostics Market Report 2026
Global Outlook – By Product Type (Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers), By Source (Nuclear Reactors, Cyclotrons), By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioscopes), By Indication (Oncology, Cardiology, Neurology, Other Indications), By End User (Hospitals, Diagnostic Imaging Centers, Academic And Research Institutes, Other End Users) - Market Size, Trends, Strategies, and Forecast to 2030
Radiopharmaceutical Theranostics Market Overview
• Radiopharmaceutical Theranostics market size has reached to $3.27 billion in 2025 • Expected to grow to $6.64 billion in 2030 at a compound annual growth rate (CAGR) of 15.3% • Growth Driver: The Surge In Cancer Incidence Boosts Radiopharmaceutical Theranostics Market Growth • Market Trend: Advancements In Theranostics For Targeted Cancer Treatment By Major Companies In Radiopharmaceutical Market • North America was the largest region in 2025.What Is Covered Under Radiopharmaceutical Theranostics Market?
Radiopharmaceutical theranostics refers to a combined approach in medicine that combines therapeutics (treatment) and diagnostics (diagnosis) using radiopharmaceuticals. These are used for patient diagnosis, therapy, and personalized management. The main product types of radiopharmaceutical theranostics are alpha emitters, beta emitters, and positron emission tomography (pet) tracers. Alpha emitters refer to radioactive substances that emit alpha particles, which are high-energy particles consisting of two protons and two neutrons. The various sources include nuclear reactors, cyclotrons, and the various radioisotopes include technetium-99, gallium-68, iodine-131, iodine-123, 18F, Y-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. These various indications include oncology, cardiology, neurology, and other indications and are used by various end-users such as hospitals, diagnostic imaging centers, academic and research institutes, and others.
What Is The Radiopharmaceutical Theranostics Market Size and Share 2026?
The radiopharmaceutical theranostics market size has grown rapidly in recent years. It will grow from $3.27 billion in 2025 to $3.76 billion in 2026 at a compound annual growth rate (CAGR) of 15.0%. The growth in the historic period can be attributed to expansion of nuclear medicine applications, increasing cancer incidence rates, advancements in radioisotope production techniques, growth in diagnostic imaging integration, early adoption of theranostic treatment models.What Is The Radiopharmaceutical Theranostics Market Growth Forecast?
The radiopharmaceutical theranostics market size is expected to see rapid growth in the next few years. It will grow to $6.64 billion in 2030 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to growing investments in precision oncology, rising demand for personalized radiopharmaceutical therapies, expansion of clinical trials for novel isotopes, increasing collaboration between diagnostics and therapeutics, ongoing innovation in isotope supply chains. Major trends in the forecast period include increasing development of targeted theranostic radiopharmaceuticals, rising use of pet-based personalized therapies, growing adoption of alpha and beta emitters in oncology, expansion of cyclotron-based isotope production, enhanced focus on precision oncology applications.
Global Radiopharmaceutical Theranostics Market Segmentation
1) By Product Type: Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers 2) By Source: Nuclear Reactors, Cyclotrons 3) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioscopes 4) By Indication: Oncology, Cardiology, Neurology, Other Indications 5) By End User: Hospitals, Diagnostic Imaging Centers, Academic And Research Institutes, Other End Users Subsegments: 1) By Alpha Emitters: Actinium-225, Radium-223, Bismuth-213, Other Alpha-Emitting Radiopharmaceuticals 2) By Beta Emitters: Iodine-131, Lutetium-177, Yttrium-90, Other Beta-Emitting Radiopharmaceuticals 3) By Positron Emission Tomography (PET) Tracers: Fluorodeoxyglucose (FDG), Gallium-68, Carbon-11, Other PET TracersWhat Is The Driver Of The Radiopharmaceutical Theranostics Market?
The rising incidence of cancer is expected to propel the growth of the radiopharmaceutical theranostics market going forward. Cancer refers to a disease or condition of complex and abnormal growth of cells that can invade and spread to other parts of the body. Radiopharmaceutical theranostics helps in cancer treatment by providing targeted and personalized approaches. For instance, in 2023, according to the American Cancer Society, a US-based voluntary cancer health organization, in the US, 1.9 million new cancer cases are estimated to be diagnosed and about 609,820 deaths may occur due to cancer. Further, 88% of the people diagnosed are expected to belong to the 50 years or above age group. Therefore, the rising incidence of cancer is driving the growth of the radiopharmaceutical theranostics industry.Key Players In The Global Radiopharmaceutical Theranostics Market
Major companies operating in the radiopharmaceutical theranostics market are Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Radiopharmaceutical Theranostics Market Trends and Insights
Major companies operating in the radiopharmaceutical theranostics market are focusing on developing theranostics aimed at curing cancer. Theranostic approaches are being explored for the treatment of rare diseases, with efforts to provide targeted therapies and diagnostic solutions for patients with limited treatment options such as cancer. For instance, in November 2023, GE HealthCare Technologies Inc., a US-based medical technology company, launched theranostics solutions for cancer. Theranostics is a new field of precision medicine that uses therapeutic agents in combination with imaging technology to identify and target cancer cells for destruction.What Are Latest Mergers And Acquisitions In The Radiopharmaceutical Theranostics Market?
In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company specializing in radiopharmaceutical products, acquired Pharma15 Corporation for $4 million. Through this acquisition, Radiopharm aims to explore the potential of next-generation radiopharmaceuticals for the treatment of prostate cancer, with a focus on surpassing PSMA-based therapies and advancing innovative solutions for patients. Pharma15 Corporation is a US-based pharmaceutical company that specializes in the development of radio-immuno-theranostics platforms and pharmaceutical products.
Regional Outlook
North America was the largest region in the radiopharmaceutical theranostics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Radiopharmaceutical Theranostics Market?
The radiopharmaceutical theranostics market includes revenues earned by providing genetic testing, targeted therapy services, contract development, and manufacturing services, consultation and interpretation, and personalized therapeutic interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Radiopharmaceutical Theranostics Market Report 2026?
The radiopharmaceutical theranostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceutical theranostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Radiopharmaceutical Theranostics Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $3.76 billion |
| Revenue Forecast In 2030 | $6.64 billion |
| Growth Rate | CAGR of 15.3% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Product Type, Source, Radioisotope, Indication, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain |
| Key Companies Profiled | Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |